David Apelian becomes CEO of Theolytics

David Apelian has become CEO of Theolytics Ltd., which is developing oncolytic immunotherapies. Apelian was CEO of BlueSphere Bio Inc. and CMO of Achillion Pharmaceuticals Inc. 

John McDonough will resign as chairman of BioPorto A/S (CSE:BIOPOR) no later than the company’s next annual general meeting. McDonough will continue in his role until a successor has been nominated...